Teva Pharmaceutical Industries Ltd. ADR (TEVA)
NYSE
41.10
+1.85 (+4.71%)
Closed
Oct 9, 2026
Day's Range
40.1242.02
52 wk Range
18.8342.02
Financial Statements - TEVA - Teva Pharmaceutical Industries Ltd. ADR
Revenue
17.25B▲ 4.3%
Net Income
1.41B▲ 172.4%Net Margin 8.2%
EBITDA
4.88B▲ 11.4%
Free Cash Flow
1.14B▲ 53.3%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 17.25B | 16.54B | 15.84B | 14.92B | 15.87B | 16.65B |
| Cost of Goods | 8.32B | 8.48B | 8.20B | 7.95B | 8.28B | 8.93B |
| Gross Profit | 8.93B | 8.06B | 7.64B | 6.97B | 7.59B | 7.72B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 3.95B | 3.36B | 3.19B | 2.69B | 3.09B | 3.05B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -1.74B | -3.59B | -2.72B | -4.85B | -1.48B | -6.50B |
| Pre Tax Income | 1.22B | -1.28B | -624M | -3.16B | 658M | -4.40B |
| Income Tax | -180M | 676M | -7M | -643M | 211M | -168M |
| Net Income | 1.41B | -1.95B | -615M | -2.49B | 456M | -4.09B |
| EPS Basic | 1.23 | -1.45 | -0.5 | -2.12 | 0.38 | -3.64 |
| EPS Diluted | 1.21 | -1.45 | -0.5 | -2.12 | 0.38 | -3.64 |
| Basic Shares Outstanding | 1.14B | 1.13B | 1.11B | 1.11B | 1.10B | 1.09B |
| Diluted Shares Outstanding | 1.14B | 1.13B | 1.11B | 1.11B | 1.10B | 1.09B |
| Ebit | 2.13B | -282M | 405M | -2.23B | 1.54B | -3.50B |
| Ebitda | 4.88B | 4.38B | 4.26B | 3.90B | 4.34B | 4.54B |
| Net Income Continuous Operations | 1.41B | -1.95B | -615M | -2.49B | 456M | -4.09B |
| Minority Interests | -7M | 320M | 56M | 53M | -39M | 109M |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
